Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,489
archived clinical trials in
Endometrial Cancer

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Memorial University Medical Center
mi
from
Savannah, GA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Northwestern University
mi
from
Chicago, IL
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Vincent Oncology Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Michigan Cancer Research Consortium NCORP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Allegiance Health
mi
from
Jackson, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Joseph Mercy Port Huron
mi
from
Port Huron, MI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Joseph Mercy Port Huron
mi
from
Port Huron, MI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Cox Medical Center South
mi
from
Springfield, MO
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Nebraska Methodist Hospital
mi
from
Omaha, NE
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Carolinas HealthCare System NorthEast
mi
from
Concord, NC
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Carolinas HealthCare System NorthEast
mi
from
Concord, NC
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Akron General Medical Center
mi
from
Akron, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Akron General Medical Center
mi
from
Akron, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Abington Memorial Hospital
mi
from
Abington, PA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Lankenau Medical Center
mi
from
Wynnewood, PA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Lankenau Medical Center
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Northwest Hospital
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Washington Medical Center
mi
from
Seattle, WA
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Saint Vincent Hospital
mi
from
Green Bay, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  9/8/2017
Bay Area Medical Center
mi
from
Marinette, WI
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 9/8/2017
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size
Status: Enrolling
Updated:  9/11/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size
Status: Enrolling
Updated: 9/11/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel Chemotherapy in Patients With Stage I-IIb Papillary Serous, Clear Cell and Endometrioid Endometrial Cancer With High-Intermediate Risk Factors
Status: Enrolling
Updated:  9/25/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Phase II Trial of Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel Chemotherapy in Patients With Stage I-IIb Papillary Serous, Clear Cell and Endometrioid Endometrial Cancer With High-Intermediate Risk Factors
Status: Enrolling
Updated: 9/25/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials